» Articles » PMID: 26959820

Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records

Overview
Journal PLoS One
Date 2016 Mar 10
PMID 26959820
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Acute Exacerbations of COPD (AECOPD) identified from electronic healthcare records (EHR) are important for research, public health and to inform healthcare utilisation and service provision. However, there is no standardised method of identifying AECOPD in UK EHR. We aimed to validate the recording of AECOPD in UK EHR.

Methods: We randomly selected 1385 patients with COPD from the Clinical Practice Research Datalink. We selected dates of possible AECOPD based on 15 different algorithms between January 2004 and August 2013. Questionnaires were sent to GPs asking for confirmation of their patients' AECOPD on the dates identified and for any additional relevant information. Responses were reviewed independently by two respiratory physicians. Positive predictive value (PPV) and sensitivity were calculated.

Results: The response rate was 71.3%. AECOPD diagnostic codes, lower respiratory tract infection (LRTI) codes, and prescriptions of antibiotics and oral corticosteroids (OCS) together for 5-14 days had a high PPV (>75%) for identifying AECOPD. Symptom-based algorithms and prescription of antibiotics or OCS alone had lower PPVs (60-75%). A combined strategy of antibiotic and OCS prescriptions for 5-14 days, or LRTI or AECOPD code resulted in a PPV of 85.5% (95% CI, 82.7-88.3%) and a sensitivity of 62.9% (55.4-70.4%).

Conclusion: Using a combination of diagnostic and therapy codes, the validity of AECOPD identified from EHR can be high. These strategies are useful for understanding health-care utilisation for AECOPD, informing service provision and for researchers. These results highlight the need for common coding strategies to be adopted in primary care to allow easy and accurate identification of events.

Citing Articles

Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes.

Ray A, Paik J, Wexler D, Sreedhara S, Bykov K, Feldman W JAMA Intern Med. 2025; .

PMID: 39928303 PMC: 11811870. DOI: 10.1001/jamainternmed.2024.7811.


Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study.

Feldman W, Suissa S, Kesselheim A, Avorn J, Russo M, Schneeweiss S BMJ. 2025; 387():e080409.

PMID: 39797646 PMC: 11684032. DOI: 10.1136/bmj-2024-080409.


Using Quantitative Bias Analysis to Adjust for Misclassification of COVID-19 Outcomes: An Applied Example of Inhaled Corticosteroids and COVID-19 Outcomes.

Bokern M, Rentsch C, Quint J, Hunnicutt J, Douglas I, Schultze A Pharmacoepidemiol Drug Saf. 2025; 34(1):e70086.

PMID: 39776023 PMC: 11706700. DOI: 10.1002/pds.70086.


Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease.

Mannino D, Weng S, Germain G, Boudreau J, Tardif-Samson A, Forero-Schwanhaeuser S Adv Ther. 2024; 42(2):1131-1146.

PMID: 39731707 PMC: 11787206. DOI: 10.1007/s12325-024-03088-1.


Medication adherence to inhalation therapy and the risk of COPD exacerbations: a systematic review with meta-analysis.

Vauterin D, Van Vaerenbergh F, Grymonprez M, Vanoverschelde A, Lahousse L BMJ Open Respir Res. 2024; 11(1).

PMID: 39304207 PMC: 11418573. DOI: 10.1136/bmjresp-2023-001964.


References
1.
Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala J, Masa F . Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004; 59(5):387-95. PMC: 1746989. DOI: 10.1136/thx.2003.008730. View

2.
Wedzicha J . Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 1(2):115-20. DOI: 10.1513/pats.2306030. View

3.
Rabe K, Hurd S, Anzueto A, Barnes P, Buist S, Calverley P . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176(6):532-55. DOI: 10.1164/rccm.200703-456SO. View

4.
Stenton C . The MRC breathlessness scale. Occup Med (Lond). 2008; 58(3):226-7. DOI: 10.1093/occmed/kqm162. View

5.
Griffin J, Lee S, Caiado M, Kesten S, Price D . Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Prim Care Respir J. 2008; 17(2):104-10. PMC: 6619881. DOI: 10.3132/pcrj.2008.00024. View